ライフサイエンスコーパス: fumagillin

1 polyenoic acids including retinoic acid and fumagillin.

2 -chain analogues of the antiangiogenic agent fumagillin.

3 of p67 in mouse C2C12 myoblasts treated with fumagillin.

4 t the same residue is covalently modified by fumagillin.

5 s the residue that is covalently modified by fumagillin.

6 lysis of the potent biological activities of fumagillin.

7 Fumagillin 1 is a meroterpenoid from Aspergillus fumigat

8 Fumagillin (1), a meroterpenoid from Aspergillus fumigat

9 iogenesis inhibitors (including angiostatin, fumagillin, 2-methoxy estradiol, transforming growth fac

10 a(nu)beta(3))- vs. alpha(nu)beta(3)-targeted fumagillin (50 mug/kg) nanoparticles.

11 Fumagillin, a naturally secreted water-insoluble antibio

12 Fumagillin, an angiogenic inhibitor, binds to methionine

13 es the formation of new blood vessels, and a fumagillin analog is currently in clinical trials as an

14 By using a fumagillin analog tagged with fluorescein, His-231 in Me

15 TNP-470, a fumagillin analog, is among the most potent and broad-sp

16 involved in this interaction, we synthesized fumagillin analogs in which each of the potentially reac

17 Herein is reported a novel fumagillin analogue named fumarranol.

18 t mouse endostatin, 20 mg.kg-1.d-1; group 2, fumagillin analogue TNP-470, 30 mg/kg every other day; a

19 We report the synthesis of a new fumagillin analogue, fumagalone, in which the spiroepoxi

20 We describe the synthesis and activity of fumagillin analogues that address the pharmacokinetic an

21 nt bond formed between a reactive epoxide of fumagillin and histidine-231 in the active site of MetAP

22 Fumagillin and ovalicin compose a class of structurally

23 Fumagillin and ovalicin constitute a family of structura

24 ctronic absorption spectroscopy we show that fumagillin and ovalicin covalently modify a conserved hi

25 with a recent structural study, suggest that fumagillin and ovalicin inhibit MetAP2 by irreversible b

26 A common target for fumagillin and ovalicin recently was identified as the t

27 peptidase-2 bound to TNP-470 and its analogs fumagillin and ovalicin revealed that these compounds ex

28 he type II enzyme is the molecular target of fumagillin and ovalicin, two epoxide-containing natural

29 eletions of 29 adjoining genes revealed that fumagillin and pseurotin are coregulated by the superclu

30 fumagillin, and pseurotin), where genes for fumagillin and pseurotin are physically intertwined in a

31 ent was treated with albendazole and topical fumagillin and responded rapidly, with no recurrence of

32 agents (minocycline, interferon alfa-2b, and fumagillin) and were stored for various durations in col

33 Endostatin, thrombospondin-1, fumagillin, and its synthetic derivative, TNP-470, are p

34 y for three natural products (fumitremorgin, fumagillin, and pseurotin), where genes for fumagillin a

35 P)] incubated with the antiangiogenesis drug fumagillin are also presented.

36 Fumagillin-based drugs inhibit MetAP-2 but not MetAP-1,

37 This fumagillin binding protein was found to be a metalloprot

38 To understand the importance of fumagillin binding to p67, we measured the level of p67

39 haracterization of three oxygenases from the fumagillin biosynthetic pathway, including a multifuncti

40 ere we report that PPI-2458, a member of the fumagillin class of irreversible methionine aminopeptida

41 rafts were treated with TNP-470, a synthetic fumagillin derivative and a well-established angiogenesi

42 These data suggest that the fumagillin derivative TNP-470 is a promising agent for t

43 The fumagillin family of natural products inhibits angiogene

44 ost potent inhibitors of angiogenesis is the fumagillin family of natural products.

45 The antiangiogenic agent fumagillin (Fg) and its analog TNP-470 bind to intracell

46 It is shown that, like fumagillin, fumarranol selectively inhibits MetAP2 and e

47 Inhibition of endothelial cell growth by fumagillin has been assumed to be mediated by inhibition

48 ximum half-life of 246 days was observed for fumagillin in samples kept in darkness at a temperature

49 These results suggest that fumagillin increases the stability of p67 and its affini

50 We show that fumagillin increases the stability of p67 by decreasing

51 Fumagillin is extensively used to control nosema disease

52 We found that the ring epoxide in fumagillin is involved in the covalent modification of M

53 The molecular target of fumagillin is methionine aminopeptidase-2 (MetAP-2).

54 In the commercial formulation, fumagillin is present as a salt in an equimolar quantity

55 An analog of fumagillin, known as TNP-470 or AGM-1470, has been under

56 rationalized by modeling based on the known fumagillin-MetAP2 crystal structure.

57 idin S, rapamycin, indolmycin, microcin B17, fumagillin, mycotoxins, Monascus pigments, and tetrameth

58 2.8% (P<0.05) with alpha(nu)beta(3)-targeted fumagillin nanoparticle treatment.

59 d with the three control groups: nontargeted fumagillin nanoparticles (1370+/-300 mm(3), P<0.05), alp

60 eted nanoparticles without drug, nontargeted fumagillin nanoparticles (30 microg/kg) or saline.

61 timplantation with alpha(nu)beta(3)-targeted fumagillin nanoparticles (30 microg/kg), alpha(nu)beta(3

62 rabbits receiving alpha(nu)beta(3)-targeted fumagillin nanoparticles (470+/-120 mm(3)) compared with

63 l tissues from animals treated with targeted fumagillin nanoparticles also showed significant decreas

64 sults suggest that alpha(nu)beta(3)-targeted fumagillin nanoparticles could provide a safe and effect

65 alpha(5)beta(1)(alpha(nu)beta(3))-fumagillin nanoparticles decreased neovasculature to neg

66 ha(nu)beta(3))- or alpha(nu)beta(3)-targeted fumagillin nanoparticles on days 7, 11, 15, and 19 postt

67 Mice that received alpha(v)beta(3)-targeted fumagillin nanoparticles showed a significantly lower di

68 lative to control; alpha(nu)beta(3)-targeted fumagillin nanoparticles were less effective (P>0.05).

69 In this study, alpha(nu)beta(3)-targeted fumagillin nanoparticles were used to suppress the neova

70 tive daily doses of alpha(v)beta(3)-targeted fumagillin nanoparticles.

71 known antiangiogenic agents (endostatin and fumagillin) on the gene expression profiles of human umb

72 ls remain responsive to inhibition by either fumagillin or a newly identified MetAp2 enzyme inhibitor

73 iated polar interactions with other parts of fumagillin provide additional affinity.

74 Comparative genomics indicates the fumagillin/pseurotin supercluster is maintained in a rap

75 MR molecular imaging of control rabbits (no fumagillin) revealed a predominant peripheral distributi

76 The structural basis for fumagillin's potency and specificity forms the starting

77 mited by toxicity of the currently available fumagillin salt.

78 We demonstrate that fumagillin selectively inhibits the S. cerevisiae MetAP-

79 and that treatment with the MetAP2 inhibitor fumagillin significantly reduces Nf1-/- astrocyte prolif

80 Fumagillin suppresses angiogenesis in cancer models and

81 The fungal metabolite fumagillin suppresses the formation of new blood vessels

82 ause racemic 5 has been converted to racemic fumagillin, this synthesis of 5 constitutes a formal syn

83 A synthetic analog of fumagillin, TNP-470, is currently undergoing clinical tr

84 highly specific as judged by the failure of fumagillin to inhibit MetAP-1 in vivo.

85 s affinity to ERKs 1 and 2 also increases in fumagillin-treated myoblasts while its affinity for eIF2

86 d to show T-cell infiltration after targeted fumagillin treatment, which was not appreciated in contr

87 more resistant to degradation in honey than fumagillin using LC-MS/MS analysis.

88 The observed half-life of fumagillin was estimated to be 3 days when exposed to li

89 TNP-470, a semisynthetic analogue of fumagillin, was studied in vitro and in the athymic nude

90 -470 parent compound, the fungal metabolite, fumagillin, we have purified a mammalian protein that is